Discussing Safety, Tolerability of Tenapanor in Pediatric IBS-C patients, with Thomas Wallach, MD - HCPLive

Discussing Safety, Tolerability of Tenapanor in Pediatric IBS-C patients, with Thomas Wallach, MD  HCPLive

At the 2025 North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN), held in Chicago, Illinois, investigators presented new interim safety findings from the phase 3 R-ALLY trial and its open-label extension evaluating tenapanor in pediatric patients with irritable bowel syndrome with constipation (IBS-C). Preliminary data demonstrated that tenapanor, a first-in-class sodium/hydrogen exchanger isoform 3 (NHE3) inhibitor, was safe and well-tolerated among adolescents, with no serious treatment-related adverse events reported.

“Tenapanor is a novel laxative that is generally thought to have some additional support for intestinal barrier function,” said Thomas Wallach, MD, Chief, Pediatric Gastroenterology, SUNY Downstate Health Sciences University, New York, New York. “It works by blocking something called NHE3, which allows... the colon to secrete more liquid into the intestine.”

View the full article